Dr. Friedman oversees a family office that focuses on private companies in the biotechnology and pharmaceutical space, with an emphasis on platform technologies, oncology, neurodegenerative disease and genomics. For several years he ran the life science screening process for NuFund (formerly Tech Coast Angels, San Diego), the largest angel investing group in the US. He currently serves on the boards of Hillhurst Bio and Trio Pharma and as observer for Conarium Bioworks, Saccharo and Switchback Therapeutics. He was a board member, served as COO and was a scientific advisor at DTx Pharma from the initial financing up to the acquisition by Novartis in 2023. Dr. Friedman is trained as a Pediatrician and Hematologist/Oncologist.